慢性膵炎(CP)治療薬の世界市場:疫学予測

◆英語タイトル:Chronic Pancreatitis (CP)- Epidemiology Forecast to 2030
◆商品コード:DELV20JU186
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年5月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(186名様閲覧)USD3,750 ⇒換算¥393,750見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算¥590,625見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Chronic Pancreatitis (CP)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease,historical &forecasted epidemiology of Chronic Pancreatitisin the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered
• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2017–2030

Chronic Pancreatitis Disease Understanding
Chronic pancreatitis (CP) is a disease characterized by a syndrome of symptoms and clinical manifestations related to functional abnormalities that develop as the result of glandular fibrosis and atrophy due to acute and chronic inflammation. CP most commonly occurs because of environmental insults, with an increased risk in patients with genetic and/or anatomic predispositions. CP may be preceded by antecedent episodes of Chronic Pancreatitis, but is increasingly recognized in patients without a prior history of AP or abdominal pain.

Chronic Pancreatitis Epidemiology
The Chronic Pancreatitis(CP) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Chronic Pancreatitis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Chronic Pancreatitis Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Prevalent cases of Chronic Pancreatitis, Diagnosed cases of Chronic Pancreatitis, Prevalence of Chronic Pancreatitis based on Etiology, Gender-specific Prevalence of Chronic Pancreatitis, Clinical manifestation of Chronic Pancreatitis) scenario of Chronic Pancreatitis (CP)in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of prevalent cases of Chronic Pancreatitis (CP) in 7 MM was found to be 395,137, in the year 2017.

Report Scope
• The report covers detailed overview of Chronic Pancreatitis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

• The report provides the insight about the historical and forecasted patient pool of Chronic Pancreatitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan

• The Report assesses the disease risk and burden and highlights the unmet needs of the disease

• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population

• The report provides the segmentation of the disease epidemiology by Prevalent cases of Chronic Pancreatitis, Diagnosed cases of Chronic Pancreatitis, Prevalence of Chronic Pancreatitis based on Etiology, Gender-specific Prevalence of Chronic Pancreatitis, Clinical manifestation of Chronic Pancreatitis in 7MM

Key strengths
• 11 Year Forecast of Chronic Pancreatitis epidemiology

• 7MM Coverage

• Total prevalent cases of CP

• Incident Cases according to segmentation: Prevalent cases, Age-specific cases, Prevalence by severity and Gender-specific cases of CP

Key assessments
• Patient Segmentation

• Disease Risk & Burden

• Risk of disease by the segmentation

• Factors driving growth in a specific patient population

【レポートの目次】

1. Key Insights

2. Executive Summary of Chronic Pancreatitis

3. SWOT Analysis for Chronic Pancreatitis

4. Chronic pancreatitis Market Overview at a Glance

4.1. Market Share (%) Distribution of CP in 2017

4.2. Market Share (%) Distribution of CP in 2030

5. Disease Background and Overview

5.1. Introduction

5.2. Associated risk factors and classification systems

5.3. Etiology

5.4. Pathophysiology

5.5. Mechanisms and Biomarkers for Progression from Recurrent Chronic Pancreatitis to Chronic Pancreatitis

5.6. Complications of CP

5.7. Diagnosis of CP

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Total Prevalent Population of Chronic Pancreatitis

7. Country Wise-Epidemiology of Chronic Pancreatitis

7.1. The United States

7.1.1. Assumptions and Rationale

7.1.2. Prevalence of Chronic Pancreatitis in the United States

7.1.3. Diagnosed cases of Chronic Pancreatitis in the United States

7.1.4. Prevalence of Chronic Pancreatitis based on Etiology in the United States

7.1.5. Gender-specific Prevalence of Chronic Pancreatitis in the United States

7.1.6. Clinical manifestation of Chronic Pancreatitis in the United States

7.2. EU-5

7.2.1. Assumptions and Rationale

7.2.2. Germany

7.2.3. France

7.2.4. Italy

7.2.5. Spain

7.2.6. United Kingdom

7.3. Japan

7.3.1. Assumptions and Rationale

7.3.2. Prevalence of Chronic Pancreatitis in Japan

7.3.3. Diagnosed cases of Chronic Pancreatitis in Japan

7.3.4. Prevalence of Chronic Pancreatitis based on Etiology in Japan

7.3.5. Gender-specific Prevalence of Chronic Pancreatitis in Japan

7.3.6. Clinical manifestation of Chronic Pancreatitis in Japan

8. Treatment and Management of Chronic Pancreatitis

8.1. Clinical management of CP

8.2. ACG Clinical Guidelines: Chronic Pancreatitis

8.3. NICE guidelines for the management of Chronic Pancreatitis

8.4. Japanese guidelines for the management of Chronic pancreatitis

8.5. Harmonizing diagnosis and treatment of chronic pancreatitis across Europe (HaPanEU) initiative

8.6. Endoscopic treatment of chronic pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

8.7. Pain in Chronic Pancreatitis

8.8. Case study

8.9. Patient Journey

9. Unmet needs

10. Appendix

10.1. Bibliography

10.2. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

Table 1: Summary of Chronic Pancreatitis (CP) Market, Epidemiology, and Key Events (2017–2030)

Table 2: Sensitivity, Specificity, Advantages, and Disadvantages of Diagnostic Tests for Chronic Pancreatitis

Table 3: Diagnosed Incident Population of Chronic Pancreatitis in 7MM (2017-2030)

Table 4: Prevalence of Chronic Pancreatitis in the United States in the United States (2017-2030)

Table 5: Diagnosed cases of Chronic Pancreatitis in the United States (2017-2030)

Table 6: Prevalence of Chronic Pancreatitis based on Etiology in the United States (2017-2030)

Table 7: Gender-specific Prevalence of Chronic Pancreatitis in the United States (2017-2030)

Table 8: Clinical manifestation of Chronic Pancreatitis in the United States (2017-2030)

Table 9: Prevalence of Chronic Pancreatitis in Germany in Germany (2017-2030)

Table 10: Diagnosed cases of Chronic Pancreatitis in Germany (2017-2030)

Table 11: Prevalence of Chronic Pancreatitis based on Etiology in Germany (2017-2030)

Table 12: Gender-specific Prevalence of Chronic Pancreatitis in Germany (2017-2030)

Table 13: Clinical manifestation of Chronic Pancreatitis in Germany (2017-2030)

Table 14: Prevalence of Chronic Pancreatitis in France in France (2017-2030)

Table 15: Diagnosed cases of Chronic Pancreatitis in France (2017-2030)

Table 16: Prevalence of Chronic Pancreatitis based on Etiology in France (2017-2030)

Table 17: Gender-specific Prevalence of Chronic Pancreatitis in France (2017-2030)

Table 18: Clinical manifestation of Chronic Pancreatitis in France (2017-2030)

Table 19: Prevalence of Chronic Pancreatitis in Italy in Italy (2017-2030)

Table 20: Diagnosed cases of Chronic Pancreatitis in Italy (2017-2030)

Table 21: Prevalence of Chronic Pancreatitis based on Etiology in Italy (2017-2030)

Table 22: Gender-specific Prevalence of Chronic Pancreatitis in Italy (2017-2030)

Table 23: Clinical manifestation of Chronic Pancreatitis in Italy (2017-2030)

Table 24: Prevalence of Chronic Pancreatitis in Spain in Spain (2017-2030)

Table 25: Diagnosed cases of Chronic Pancreatitis in Spain (2017-2030)

Table 26: Prevalence of Chronic Pancreatitis based on Etiology in Spain (2017-2030)

Table 27: Gender-specific Prevalence of Chronic Pancreatitis in Spain (2017-2030)

Table 28: Clinical manifestation of Chronic Pancreatitis in Spain (2017-2030)

Table 29: Prevalence of Chronic Pancreatitis in the United Kingdom in the United Kingdom (2017-2030)

Table 30: Diagnosed cases of Chronic Pancreatitis in the United Kingdom (2017-2030)

Table 31: Prevalence of Chronic Pancreatitis based on Etiology in the United Kingdom (2017-2030)

Table 32: Gender-specific Prevalence of Chronic Pancreatitis in the United Kingdom (2017-2030)

Table 33: Clinical manifestation of Chronic Pancreatitis in the United Kingdom (2017-2030)

Table 34: Diagnosed Incidence of AP by Etiology in the UK (2017-2030)

Table 35: Diagnosed Incidence of AP by Severity in the UK (2017-2030)

Table 36: Diagnosed Incidence of AP by Gender in the UK (2017-2030)

Table 37: Diagnosed Incidence of Recurrent AP Cases in the UK (2017-2030)

Table 38: Prevalence of Chronic Pancreatitis in Japan in Japan (2017-2030)

Table 39: Diagnosed cases of Chronic Pancreatitis in Japan (2017-2030)

Table 40: Prevalence of Chronic Pancreatitis based on Etiology in Japan (2017-2030)

Table 41: Gender-specific Prevalence of Chronic Pancreatitis in Japan (2017-2030)

Table 42: Clinical manifestation of Chronic Pancreatitis in Japan (2017-2030)

Figure 1: SWOT Analysis

Figure 2: TIGAR-O risk factor classification system

Figure 3: Effects of ethanol on acinar and pancreatic stellate cells

Figure 4: Pathophysiology of chronic pancreatitis

Figure 5: Pathophysiology of chronic pancreatitis

Figure 6: Prevalent Population of Chronic Pancreatitis in 7MM (2017-2030)

Figure 7: Prevalence of Chronic Pancreatitis in the United States in the United States (2017-2030)

Figure 8: Diagnosed cases of Chronic Pancreatitis in the United States (2017-2030)

Figure 9: Prevalence of Chronic Pancreatitis based on Etiology in the United States (2017-2030)

Figure 10: Gender-specific Prevalence of Chronic Pancreatitis in the United States (2017-2030)

Figure 11: Clinical manifestation of Chronic Pancreatitis in the United States (2017-2030)

Figure 12: Prevalence of Chronic Pancreatitis in Germany in Germany (2017-2030)

Figure 13: Diagnosed cases of Chronic Pancreatitis in Germany (2017-2030)

Figure 14: Prevalence of Chronic Pancreatitis based on Etiology in Germany (2017-2030)

Figure 15: Gender-specific Prevalence of Chronic Pancreatitis in Germany (2017-2030)

Figure 16: Clinical manifestation of Chronic Pancreatitis in Germany (2017-2030)

Figure 17: Prevalence of Chronic Pancreatitis in France in France (2017-2030)

Figure 18: Diagnosed cases of Chronic Pancreatitis in France (2017-2030)

Figure 19: Prevalence of Chronic Pancreatitis based on Etiology in France (2017-2030)

Figure 20: Gender-specific Prevalence of Chronic Pancreatitis in France (2017-2030)

Figure 21: Clinical manifestation of Chronic Pancreatitis in France (2017-2030)

Figure 22: Prevalence of Chronic Pancreatitis in Italy in Italy (2017-2030)

Figure 23: Diagnosed cases of Chronic Pancreatitis in Italy (2017-2030)

Figure 24: Prevalence of Chronic Pancreatitis based on Etiology in Italy (2017-2030)

Figure 25: Gender-specific Prevalence of Chronic Pancreatitis in Italy (2017-2030)

Figure 26: Clinical manifestation of Chronic Pancreatitis in Italy (2017-2030)

Figure 27: Prevalence of Chronic Pancreatitis in Spain in Spain (2017-2030)

Figure 28: Diagnosed cases of Chronic Pancreatitis in Spain (2017-2030)

Figure 29: Prevalence of Chronic Pancreatitis based on Etiology in Spain (2017-2030)

Figure 30: Gender-specific Prevalence of Chronic Pancreatitis in Spain (2017-2030)

Figure 31: Clinical manifestation of Chronic Pancreatitis in Spain (2017-2030)

Figure 32: Prevalence of Chronic Pancreatitis in the United Kingdom (2017-2030)

Figure 33: Diagnosed cases of Chronic Pancreatitis in the United Kingdom (2017-2030)

Figure 34: Prevalence of Chronic Pancreatitis based on Etiology in the United Kingdom (2017-2030)

Figure 35: Gender-specific Prevalence of Chronic Pancreatitis in the United Kingdom (2017-2030)

Figure 36: Clinical manifestation of Chronic Pancreatitis in the United Kingdom (2017-2030)

Figure 37: Prevalence of Chronic Pancreatitis in Japan in Japan (2017-2030)

Figure 38: Diagnosed cases of Chronic Pancreatitis in Japan (2017-2030)

Figure 39: Prevalence of Chronic Pancreatitis based on Etiology in Japan (2017-2030)

Figure 40: Gender-specific Prevalence of Chronic Pancreatitis in Japan (2017-2030)

Figure 41: Clinical manifestation of Chronic Pancreatitis in Japan (2017-2030)

Figure 42: Diagnostic path for chronic pancreatitis

Figure 43: Therapeutic path for chronic pancreatitis

Figure 44: Patient journey for chronic pancreatitis

Figure 45 Unmet needs for Chronic pancreatitis

Figure 46: Market Drivers

Figure 47: Market barriers

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[慢性膵炎(CP)治療薬の世界市場:疫学予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆